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ABSTRACT
Acute kidney injury (AKI) has gained significant attention following patient safety alerts about the increased risk of harm to
patients, including increased mortality and hospitalization. Common causes of AKI include hypovolaemia, nephrotoxic
medications, ischaemia and acute glomerulonephritis, although in reality it may be undetermined or multifactorial.
A period of inflammation either as a contributor to the kidney injury or resulting from the injury is almost universally seen.
This article was compiled following a workshop exploring the interplay between injury and inflammation. AKI is
characterized by some degree of renal cell death through either apoptosis or necrosis, together with a strong inflammatory
response. Studies interrogating the resolution of renal inflammation identify a whole range of molecules that are
upregulated and confirm that the kidneys are able to intrinsically regenerate after an episode of AKI, provided the threshold
of damage is not too high. Kidneys are unable to generate new nephrons, and dysfunctional or repeated episodes will lead
to further nephron loss that is ultimately associated with the development of renal fibrosis and chronic kidney disease
(CKD). The AKI to CKD transition is a complex process mainly facilitated by maladaptive repair mechanisms. Early
biomarkers mapping out this process would allow a personalized approach to identifying patients with AKI who are at high
risk of developing fibrosis and subsequent CKD. This review article highlights this process and explains how laboratory
models of renal inflammation and injury assist with understanding the underlying disease process and allow interrogation
of medications aimed at targeting the mechanistic interplay.
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INTRODUCTION
Over the past few years, acute kidney injury (AKI) has gained
significant attention following patient safety alerts about the in-
creased risks of harm to patients who experience an episode of
AKI. It is estimated that one in five emergency admissions into
hospital is associated with AKI [1] and that one in three patients
in hospital with AKI develops it while in hospital [2]. AKI is re-
sponsible for prolonging inpatient care and contributing to
~100 000 deaths annually in the UK [3]. AKI is defined as a sud-
den alteration in the function of the kidney due to a variety of
causes. It is typically reported in terms of measurable clinical
outcomes, with an increase in the serum creatinine concentra-
tion and/or a reduction in the patient’s urine output being the
most universally recognized definition [4]. These measurable
outcomes define whether a patient has clinical features of AKI
and they have improved standardization across clinical settings
and research studies. However, they tell us very little about the
underlying cause or mechanisms that have led to the injury it-
self. The most common causes of AKI include hypovolaemia,
nephrotoxic medications, ischaemia and acute glomerulone-
phritis, although in reality it may be undetermined or multifac-
torial [5, 6]. Within the mechanisms of AKI, one likely area of
consistency is a period of inflammation either as a contributor
or as a consequence of the renal injury, for example, systemic
lupus erythematosus as an inflammatory disease causing
glomerulonephritis or nephrotoxic kidney injury causing local
renal inflammation, respectively. This article was compiled as a
result of a multispecialty kidney injury and inflammation event
attended by the authors. The aim of this review is to discuss the
complex interplay between kidney injury and inflammation
with regard to its mechanisms, diagnosis and potential targets
for treatment. It also aims to consider future directions for
further research to help improve our understanding of this
disease process and improve the clinical outcomes of our
patients.
CELLULAR AND MOLECULAR MECHANISMS OF
INFLAMMATION IN RESPONSE TO RENAL
INJURY
Understanding the cellular and molecular mechanisms that
lead to renal inflammation is one of the most promising ways
to identify early targets for treatment or prevention of AKI
(Figure 1). Inflammation is a physiological process designed to
protect the body against an acute injurious stimulus, such as
ischaemia, toxins or pathogens. In a healthy individual, these
stimuli are initially detected by the kidney through immune
cells that include not only tissue-resident dendritic cells and
macrophages, but also native renal cells that are able to express
receptors for sensing damage (for excellent recent reviews on
the interactions between kidneys and the immune system, the
reader is directed to Ernandez et al. [7] and Tecklenborg et al. [8]).
These intrarenal immune cells respond to such stimuli by ac-
tively secreting cytokines such as interleukin (IL)-1 and IL-6 and
chemokines such as monocyte chemoattractant protein-1,
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FIGURE 1: Cellular and molecular mechanisms of inflammation. Kidney damage is recognized by resident renal cells, dendritic cells and macrophages (as shown in
area 1). Their response of cytokine and chemokine secretion is the current target for most treatments (area 2). Cytokine release triggers leucocyte recruitment to the
side of damage beginning with the non-specific pathogen destruction of neutrophils (area 3). Monocytes are recruited to release further cytokine damage and differen-
tiate into phagocytosing macrophages for the removal of apoptotic cells and damaged tissue to restore tissue homeostasis (area 4). Resolution of the damaged tissue is
often accomplished by lipid mediators that could be the future targets for medical treatments of chronic inflammatory diseases.
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which migrate to nearby blood vessels and recruit leucocytes
from the circulation to the area of damage to destroy invading
pathogens, repair damaged tissue and restore tissue homeosta-
sis [9].
The recruitment of leucocytes to the kidney occurs in a
sequential manner to efficiently repair damage and restore
renal function. Neutrophils are usually the first to be recruited
to the area, as these cells are non-specific and are able to re-
lease their toxic granule contents to destroy invading pathogens
at the site of inflammation [10]. However, as this is non-specific,
these cells are also able to induce tissue damage and thus a sec-
ond phase of monocytes is recruited from the bloodstream.
These cells are more specific and can be subdivided into two
groups: M1 and M2 monocytes. M1 monocytes release cytokines
to destroy any pathogens that were not destroyed by the neu-
trophils. M2 monocytes differentiate into macrophages
and phagocytose damaged tissue and apoptotic neutrophils to
restore homeostasis to the tissue [11].
Studies interrogating the resolution of renal inflammation in
acute inflammatory models identified a whole range of mole-
cules that are increased in the tissue during the resolution
phase of inflammation [12]. These molecules are most com-
monly lipid mediators that are released by neutrophils and
monocytes at the site of inflammation, where they act to reduce
the infiltration of neutrophils and promote the phagocytic
clearance of apoptotic cells by macrophages [13]. Many in vitro
and in vivo studies have been performed assessing the role of
these lipid mediators in preventing or treating AKI. They have
been shown to mitigate sepsis-associated AKI [14], improve
tubular function after kidney ischaemia–reperfusion (KIR) injury
[15] and blunt the development of lupus nephritis in lupus-
prone New Zealand Black  New Zealand White (NZB/W) F1
mice[16].
AKI AND ITS PROGRESSION TO CHRONIC
KIDNEY DISEASE (CKD)
Irrespective of the underlying cause, AKI is characterized by
some degree of renal cell death through either apoptosis or ne-
crosis and a strong inflammatory response [17, 18]. More recent
studies have demonstrated evidence of necroptosis, ferroptosis,
parthanatos and mitochondrial permeability transition-induced
regulated necrosis [19]. These all represent different pathways
leading to an inflammatory response and thus different targets
for potential AKI therapeutic development. While epithelial
cells of the proximal tubule are mostly affected in the main
causes of AKI, there is also significant damage to the endothe-
lial and smooth muscle cells and obviously a predominance of
glomerular damage in AKI due to glomerulonephritis [20, 21].
Studies have demonstrated that podocyte injury precedes tubu-
lar injury and can be seen as early as 30 min post-reperfusion in
KIR injury in mice [22]. After the initial injury, surviving cells
undergo a process of dedifferentiation and proliferation to re-
place damaged cells and restore integrity [23–25]. Previous stud-
ies have indicated that the kidneys are able to intrinsically
regenerate after an episode of AKI provided that the threshold
of damage is not too high [26, 27].
However, kidneys are unable to generate new nephrons, and
maladaptive or repeated episodes of AKI will lead to further
nephron loss and injury that is ultimately associated with CKD
and end-stage renal disease (ESRD) [26–28]. In addition, a single
episode of AKI puts patients at risk of future episodes of AKI,
which, in combination with individual modifiers, increases the
risk of developing CKD and ESRD [29, 30] (Figure 2). The AKI to
CKD transition is a complex process that was reviewed recently
by Sato and Yanagita [31]. The transition is mainly facilitated by

















FIGURE 2: A summary of the pathway determining an individual patient’s outcome of AKI. A patient experiences an episode of AKI following a certain stimuli, such as
sepsis or ischaemia, resulting in an inflammatory process that can be modified by an individual’s genetic predisposition and may be further insulted by primary modi-
fiers including age and pre-existing disease. Secondary modifiers include additional hits such as haemodynamic instability, nephrotoxic pharmacotherapy or other
interventions (radiological investigations). These impact on the subsequent inflammatory response and the eventual AKI outcome.
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process of dedifferentiation can lead to failed tubule recovery, a
decrease in epithelial markers and an increase in mesenchymal
markers [25, 33, 34]. Damaged tubules, as well as immune cell–
derived myofibroblasts, are a source of pro-fibrotic factors and
are associated with the subsequent development of fibrosis and
scarring. Whereas the process of fibrosis is meant to prevent
further damage, it also reduces renal function by promoting
capillary rarefaction and exacerbating hypoxia and atrophia [32,
34, 35]. Currently >100 therapies have proven effective in
animal models of AKI and yet none are effective in preventing
AKI in people or preventing the transition from AKI to CKD [36].
Understanding the complex interaction between renal inflam-
mation and injury may allow earlier identification and subse-
quent intervention to prevent the onset of irreversible fibrosis.
CLINICAL EXAMPLES OF AKI AND ITS
INFLAMMATORY MECHANISMS
One must consider the clinical context in which kidney injury
or inflammation has occurred: in several cases, the injury and/
or inflammation may be sequelae of ongoing systematic disease
or even due to genetic disorders or acquired injuries where in-
flammation may not classically be considered. Below we outline
some clinical examples that either directly or indirectly affect
kidney function and explore what factors may limit treatment
options.
AKI following cardiac bypass surgery
The process of cardiopulmonary bypass is acknowledged to
cause sudden alterations in renal perfusion, with consequent
ischaemia and reperfusion cycles [37]. During ischaemia,
aerobic respiration within mitochondria ceases. The metabo-
lites of the citric acid cycle, required for aerobic respiration
via electron transport, become depleted, except for succinate,
which accumulates during ischaemia [38]. Upon reperfusion the
accumulated succinate in mitochondria is rapidly oxidized,
driving superoxide formation via reverse electron transport
at complex I of the electron transport chain [38]. This burst of
superoxide [39, 40] is then followed by further superoxide for-
mation via the xanthine oxidase pathway and nicotinamide ad-
enine dinucleotie phosphate oxidases [41]. Production of
reactive oxygen species (ROS) activates a variety of pathways
that lead to tissue injury. These include opening of the mito-
chondrial permeability transition pore, leading to apoptosis or
necrosis, and induction of damage-associated molecular pat-
terns, leading to activation of both innate and adaptive immune
responses [42]. Production of ROS also induces pro-
inflammatory transcription factors such as nuclear factor jB
[43], leading to recruitment of inflammatory cells to the renal
parenchyma and the potential for fibrosis [44]. Clinically be-
tween 30 and 50% of patients develop AKI following cardiopul-
monary bypass surgery [45] and strategies to ameliorate this in
adults have included large randomized controlled trials to eval-
uate the use of perioperative methylprednisolone, but with little
benefit [46]. Typically patients have a period of AKI spanning
several days while the repair mechanisms restore renal func-
tion. Of those with AKI, many (12% in congenital heart disease)
will develop CKD within 5 years [45].
Autosomal dominant polycystic kidney disease
Autosomal dominant polycystic kidney disease has tradition-
ally been considered a disease of adulthood, however, chronic
inflammation is observed early in this disorder, with M1 and M2
macrophages modulating fibrosis and increasing deposition of
extracellular matrix to which inflammatory cells are recruited
[47]. In mouse models, ablation of the adhesion molecule b1
integrin reduces both the formation of cysts and fibrosis [48],
suggesting that crosstalk between extracellular matrix and
inflammatory cytokines may be a fruitful approach to disease
management. Likewise, the physical presence of cysts in these
patients makes controlling infection and inflammation difficult:
antibiotics have some difficulty in penetrating infected kidney
cysts, which makes urinary tract infections more damaging [49].
A recent development in this condition has seen the introduc-
tion of an effective pharmacological treatment to suppress the
growth of kidney cysts using the vasopressin inhibitor
tolvaptan [50] and preclinical studies are evaluating adenosine
monophosphate–activated protein kinase as a signalling target
[51].
Lowe syndrome/Dent2 disease
These are rare multisystemic X-linked disorders affecting brain,
kidney, eyes and bone. The kidney disorder manifests in defec-
tive resorption of metabolites in the proximal tubule, leading, if
untreated, to rickets, aminoaciduria and disturbance of para-
thyroid hormone signalling [52]. Treatments are lifelong supple-
mentation of metabolites and close management of symptoms.
These patients frequently develop kidney stones due to exces-
sive calcium loss [52], which then deposits in the kidney, caus-
ing a progressive process of kidney scarring and fibrosis leading
to ESRD between the second and fourth decades of life. Work in
model systems suggests that defects in the causative gene
OCRLinositol polyphosphate-5-phosphatase (OCRL) also mani-
fest as increased amplification of inflammatory immune signal-
ling [53]. Interestingly, Lowe syndrome patients frequently
exhibit tenosynovitis, joint swelling and arthritis [54], which
may indicate immune misregulation. This has been reversed in
animal models by injection of virally encoded OCRL to affected
chondrocytes [55], although this is not yet a therapy that can be
deployed in humans.
FUTURE DIRECTIONS
Earlier detection using biomarkers
Standard clinical practice continues to focus on changes in
serum creatinine and urine output as markers of kidney injury
despite research on novel biomarkers receiving increased
attention over the last 15 years [56]. The ongoing success of cre-
atinine as the biomarker of choice is derived from the fact that
it is endogenous, easily measured, well-validated and used in
formal staging criteria. Creatinine’s limitations are the relative
requirement to have a comparative baseline value to aid inter-
pretation, non-glomerular elimination via the proximal tubule
and gastrointestinal tract and interference from commonly pre-
scribed drugs [57]. A number of exogenous markers can be mea-
sured in the blood, urine and via nuclear imaging [58]. The use
of exogenous markers of injury and function is much less fre-
quently favoured due to the added technical complexity and ad-
ditional expense. However, markers such as technetium-99m
diethylenetriaminepentaacetate give useful additional informa-
tion about the, for example, differential function between kid-
neys (split function).
Current clinical practice to measure renal inflammation
remains limited. Renal histology remains the gold standard and
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is usually required in the diagnosis of acute glomerulonephritis
[59]. However, interobserver variability can be poor, as demon-
strated in a study assessing renal histology slides from patients
with lupus nephritis [60]. Examining the urine for sediment and
casts seems to have fallen out of favour, but in trained hands it
can provide a wealth of information [61]. Glomerular
inflammation may be inferred from the degree of proteinuria
and serological markers such as C-reactive protein, erythrocyte
sedimentation rate and eosinophilia may be suggestive of in-
flammatory conditions but are not renal specific.
Novel markers can be categorized as endogenous or exoge-
nous. They can be measured in the serum, urine or via imaging
methods. A list of considered biomarkers for AKI is presented in
Table 1. Criticisms of these markers include the limited clinical
settings that these are tested in, their role when measured in
isolation, as recent studies have suggested the need to develop
an AKI panel to compensate for specificity and sensitivity defi-
ciencies, and that some markers may be generated extrarenally
(e.g. neutrophil gelatinase-associated lipocalin in states of in-
fection or physiological stress [62, 75]). In a clinical setting, an
endogenous marker would be preferable to simplify the techni-
cal process in large patient groups. Due to its obvious proximity,
urine has been implicated as the best site for early detection of
kidney injury [75], but despite many of these novel biomarkers
appearing within the literature, none of these are in routine
clinical use.
Targets to modify AKI outcome
Treatment options in AKI remain experimental and, aside from
treating the underlying cause, current clinical management for
AKI is conservative, with careful fluid and electrolyte control
and supportive renal replacement therapy when indicated.
Virtually all immune cells are implicated in the pathogenesis of
AKI and blockade of several innate immune receptors (e.g. toll-
like receptor 2) has been shown to ameliorate experimental AKI
in animal models, although their translation into clinical prac-
tice is uncertain [36]. Targeting pro-fibrotic signalling cascades
may be another useful way to modify AKI, for example, fibro-
blast growth factor 23 (FGF23) induces pro-fibrotic signalling via
activation of the transforming growth factor (TGF)-b pathway in
kidney cells primed with injury. Individual genetic variants may
predispose patients to increased concentrations of FGF23 and
modify the inflammatory response to acute injury stimuli [76].
Direct inhibitors specifically targeting FGF23 are not available.
However, it may be indirectly reduced by inhibition of
the renin–angiotensin–aldosterone system. Post-translational
modification proteins called small ubiquitin-related modifiers
are extensively expressed in eukaryotes and influence the in-
dividual response to the activation of the nuclear factor jB in-
flammatory signalling pathway. Therefore they play a central
regulatory role in the inflammatory response and may have a
role in contributing to the TGF-b/Smad pathway, leading to fi-
brosis of the kidney [77].
Preclinical modelling of AKI
Part of the reason for the limited treatment options is the
inability of existing preclinical disease models to accurately
recapitulate kidney injury. Additionally, the lack of validated
AKI biomarkers has resulted in a disconnect and ultimately
poor translation between preclinical and clinical models [78].
Inflammation and kidney injury are tightly coupled and for a
model to be useful for the study of mechanisms or to assist with
drug discovery, it needs to incorporate this cyclical phenome-
non. However, modelling of this complexity is difficult, with
researchers subsequently forced to strike a balance between the
scalability of an experimental model and the degree of disease
homology (Figure 3).
The approach with the greatest scalability is in silico model-
ling, which uses bioinformatics and chemoinformatics to
hypothesize and test during drug discovery [79]. These methods
are capable of screening virtual compound libraries and simu-
lating their binding using structural data. However, computa-
tional approaches are limited by our understanding of the
binding targets in question [80] and are held back by biomarker
discrepancies [78]. In addition, in silico models are often vali-
dated using poor in vitro models, thus reducing disease
Table 1. A summary of the urine biomarkers implicated in renal in-
jury and inflammation








Kidney injury molecule-1 IL-1-b
Cystatin C Tumour necrosis
factor-a
IL-6 and -18 IL-8
Retinol-binding protein IL-18
Glutathione S-transferase (a, g, p) IL-12
Urinary insulin-like growth factor-
binding protein 7
Interferon c




Micro-ribonucleic acids IL-1 receptor antagonist
Naþ/Hþ exchanger isoform 3 IL-4
Perforin TGF-b






Liver-type fatty acid-binding protein Leptin
Netrin-1 CD163
Clusterin Vascular cell adhesion
molecule-1
b2-microglobulin E-selectin











detection, e.g. fluorescein isothiocy-
anate–sinistrin
Dickkopf-3
Many urinary biomarkers have been evaluated to determine their role in the
early identification of renal injury and inflammation within the literature, as
demonstrated within this table. While many are implicated in isolation, their
strength is evident once combined to produce a panel of biomarkers.
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homology. Two-dimensional cell models are also highly scal-
able and conditionally immortalized human podocytes [81], glo-
merular endothelial cells [82] and mesangial cells [83] are used
routinely to model kidney disease in vitro. For high-throughput
assays, cells are often grown in monoculture on culture plastic
in a way far removed from their in vivo niche. For podocytes,
this has been shown to deleteriously affect proteome and tran-
scriptome readouts, hampering their capacity for simulating
disease [84].
It is apparent that co-culturing renal cells in three dimen-
sions helps to better recapitulate the three-dimensional archi-
tecture and signalling environment of in vivo tissue [85, 86].
Moreover, these bioengineered models of acute and chronic in-
jury offer superior toxicology sensitivity than their two-dimen-
sional cultured counterparts [87]. However, models such as this
are far less scalable and reproducible than two-dimensional cell
models and as such are not suitable for high-throughput
screening. Kidney-on-a-chip approaches seek to add flow to cul-
tured cells and have successfully bioengineered a kidney tubule
from conditionally immortalized human proximal tubule epi-
thelial cells [88]. It is also possible for multiorgan systems to be
established, including sequentially connected gut, liver and kid-
ney cells [89]. These models have the potential to simulate the
cyclical nature of kidney injury, although they are currently
very low throughput, impeding their usefulness for screening.
The advent of kidney organoids from induced pluripotent
stem cells represents a significant step in the right direction
for improving disease homology of in vitro models [90]. These sys-
tems have the potential to model genetically acquired disease
such as Alport syndrome [91]. Improving the scalability of these
models is once again a challenge, however, if they are to be used
for drug screening. In vivo animal disease models (despite model-
ling non-human disease) currently offer the greatest simulation
of the many comorbidities that underpin kidney injury. Among
these, rodent models of ischaemia-reperfusion [92] and uretic ob-
struction [93] are most ubiquitous. However, it is not possible to
use animal models for the early stages of compound screening,
which means that cell models must first be used.
There is a clear need for refinement in the high-throughput
models used in the early stages of drug discovery. An in vitro
model of kidney injury that is jointly scalable and representa-
tive of the disease, with transferable biomarker readouts, would
drastically improve the translation between preclinical and
clinical models.
CONCLUSIONS
Historically the lack of consensus definitions for AKI and a
limited understanding of the pathophysiology of AKI has
impeded advances in the management of these patients and
the development of new treatments. The advent of a widely ac-
cepted definition of AKI has opened the way for more valuable
research in this field. Here we have considered the role of in-
flammation within the mechanism of kidney injury and identi-
fied future directions for research that will translate into
improved understanding of mechanisms to benefit patients.
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20. Tögel F, Weiss K, Yang Y et al. Vasculotropic, paracrine
actions of infused mesenchymal stem cells are important to
the recovery from acute kidney injury. Am J Physiol Renal
Physiol 2007; 292: F1626–F1635
21. Basile DP. The endothelial cell in ischemic acute kidney in-
jury: implications for acute and chronic function. Kidney Int
2007; 72: 151–156
22. Chen Y, Lin L, Tao X et al.The role of podocyte damage in the
etiology of ischemia-reperfusion acute kidney injury and
post-injury fibrosis. BMC Nephrol 2019; 20:106
23. Witzgall R, Brown D, Schwarz C et al. Localization of prolifer-
ating cell nuclear antigen, vimentin, c-Fos, and clusterin in
the postischemic kidney. Evidence for a heterogenous ge-
netic response among nephron segments, and a large pool
of mitotically active and dedifferentiated cells. J Clin Invest
1994; 93: 2175–2188
24. Kusaba T, Lalli M, Kramann R et al. Differentiated kidney epi-
thelial cells repair injured proximal tubule. Proc Natl Acad Sci
USA 2014; 111: 1527–1532
25. Shu S, Zhu J, Liu Z et al. Endoplasmic reticulum stress is acti-
vated in post-ischemic kidneys to promote chronic kidney
disease. EBioMedicine 2018; 37: 269–280
26. Humphreys BD, Valerius MT, Kobayashi A et al. Intrinsic epi-
thelial cells repair the kidney after injury. Cell Stem Cell 2008;
2: 284–291
27. Anders HJ. Immune system modulation of kidney regenera-
tion—mechanisms and implications. Nat Rev Nephrol 2014;
10: 347–358
28. Huen SC, Cantley LG. Macrophage-mediated injury and re-
pair after ischemic kidney injury. Pediatr Nephrol 2015; 30:
199–209
29. John D, Imig MJR. Immune and inflammatory role in renal dis-
ease. Compr Physiol 2014; 3: 957–976
30. Jang HR, Rabb H. Immune cells in experimental acute kidney
injury. Nat Rev Nephrol 2015; 11: 88–101
31. Sato Y, Yanagita M. Immune cells and inflammation in AKI
to CKD progression. Am J Physiol Renal Physiol 2018; 315:
F1501–F1512
32. Basile DP, Bonventre JV, Mehta R et al. Progression after AKI:
understanding maladaptive repair processes to predict and
identify therapeutic treatments. J Am Soc Nephrol 2016; 27:
687–697
33. Kang HM, Ahn SH, Choi P et al. Defective fatty acid oxidation
in renal tubular epithelial cells has a key role in kidney fibro-
sis development. Nat Med 2015; 21: 37–46
34. Venkatachalam MA, Weinberg JM, Kriz W et al. Failed tubule
recovery. J Am Soc Nephrol 2015; 26: 1765–1776
35. Norman JT, Fine LG. Intrarenal oxygenation in chronic renal
failure. Clin Exp Pharmacol Physiol 2006; 33: 989–996
36. Okusa MD, Rosner MH, Kellum JA et al. Therapeutic targets
of human AKI: harmonizing human and animal AKI. J Am
Soc Nephrol 2016; 27: 44–48
37. O’Neal JB, Shaw AD, Billings FT. Acute kidney injury follow-
ing cardiac surgery: current understanding and future direc-
tions. Crit Care 2016; 20: 187
38. Chouchani ET, Pell VR, Gaude E et al. Ischaemic accumula-
tion of succinate controls reperfusion injury through mito-
chondrial ROS. Nature 2014; 515: 431–435
39. Chouchani ET, Pell VR, James AM et al. A unifying mecha-
nism for mitochondrial superoxide production during
ischemia-reperfusion injury. Cell Metab 2016; 23: 254–263
40. Jassem W, Fuggle SV, Rela M et al. The role of mitochondria in
ischemia/reperfusion injury. Transplantation 2002; 73: 493–499
41. Kezic A, Stajic N, Thaiss F. Innate immune response in kid-
ney ischemia/reperfusion injury: potential target for ther-
apy. J Immunol Res 2017; 2017: 1–10
42. Martin JL, Gruszczyk AV, Beach TE et al. Mitochondrial mech-
anisms and therapeutics in ischaemia reperfusion injury.
Pediatr Nephrol 2019; 34: 1167–1174
43. Wei C, Li L, Kim IK et al. NF-jB mediated miR-21 regulation in
cardiomyocytes apoptosis under oxidative stress. Free Radic
Res 2014; 48: 282–291
44. Schrier RW. Diseases of the Kidney and Urinary Tract, 8th ed.
Philadelphia: Lippincott, Williams and Wilkins, 2007
45. Madsen NL, Goldstein SL, Frøslev T et al. Cardiac surgery in
patients with congenital heart disease is associated with
acute kidney injury and the risk of chronic kidney disease.
Kidney Int 2017; 92: 751–756
46. Garg AX, Chan MT, Cuerden MS et al. Effect of methylpred-
nisolone on acute kidney injury in patients undergoing car-
diac surgery with a cardiopulmonary bypass pump: a
randomized controlled trial. CMAJ 2019; 191: E247–E256
47. Bergmann C, Guay-Woodford LM, Harris PC et al. Polycystic
kidney disease. Nat Rev Dis Primers 2018; 4: 51
48. Lee K, Boctor S, Barisoni LMC et al. Inactivation of integrin-b1
prevents the development of polycystic kidney disease after
the loss of polycystin-1. J Am Soc Nephrol 2015; 26: 888–895
49. Anselmo A, Iaria G, Pellicciaro M et al. Native nephrectomy
in patients with autosomal dominant polycystic kidney






/ckj/advance-article/doi/10.1093/ckj/sfaa164/5934685 by guest on 24 O
ctober 2020
disease evaluated for kidney transplantation. Transplant Proc
2019; 51: 2914–2916
50. Poch E, Rodas L, Blasco M et al. An update on tolvaptan for
autosomal dominant polycystic kidney disease. Drugs Today
2018; 54: 519–533
51. Leonhard WN, Song X, Kanhai AA et al. Salsalate, but not
metformin or canagliflozin, slows kidney cyst growth in an
adult-onset mouse model of polycystic kidney disease.
EBioMedicine 2019; 47: 436–445
52. Bockenhauer D, Bokenkamp A, van’t Hoff W et al. Renal phe-
notype in Lowe syndrome: a selective proximal tubular dys-
function. Clin J Am Soc Nephrol 2008; 3: 1430–1436
53. Del Signore SJ, Biber SA, Lehmann KS et al. dOCRL maintains
immune cell quiescence by regulating endosomal traffic.
PLoS Genet 2017; 13: e1007052
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